CATO SMS Appoints Vice President of Regulatory Strategy, Cell and Gene Therapy – PRNewswire

Posted: October 3, 2021 at 2:11 am

Dr. Lee joins CATO SMS from AstraZeneca where she was medical director responsible for medical monitoring and assessment of safety-related issues throughout the life cycle of immuno-oncology products.Highlights of Dr. Lee's previous experience include:

"Dr. Lee brings to our team a unique blend of extensive clinical and regulatory experience," said Mark A. Goldberg, M.D., executive chairman, CATO SMS. "Dr. Lee's background working as a senior regulator and as a physician caring for patients will provide invaluable perspective and guidance to our small and emerging biopharmaceutical clients who are focused on developing cell and gene therapies for the treatment of cancer."

Dr. Lee earned her doctorate in neuroscience from Johns Hopkins University School of Medicine in Baltimore. She earned her doctor of medicine degree from the National Yang-Ming University School of Medicine in Taipei, Taiwan.

About CATO SMS CATO SMS is a global provider of clinical research solutions, including strategic consulting and full-service clinical trial operations. With more than 30 years of experience focusing on the needs of small and emerging biopharmaceutical companies, CATO SMS effectively designs and executes studies from strategy to approval in complex indications and modalities across a variety of therapeutic areas with a proven center of excellence in oncology. CATO SMS' regulatory, therapeutic and operational expertise enables the company to meet goals and exceed expectations. Visit CATO-SMS.comfor more information.

SOURCE CATO SMS

Visit link:
CATO SMS Appoints Vice President of Regulatory Strategy, Cell and Gene Therapy - PRNewswire

Related Post